ENDRA Life Sciences Inc. (NDRA) Income Statement
NDRA 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsNDRA revenue and net income
NDRA profit margins
NDRA growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
NDRA quarterly EPS vs estimates
ENDRA Life Sciences beat the analyst EPS estimate in 6 of the last 8 quarters. Next report: November 13, 2026 (estimate $-0.84).
NDRA income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $6,174 | $351,622 | $515,582 |
| Cost of revenue | — | $206,172 | $275,451 | $234,258 | $224,415 | $165,249 | $115,011 | $0 | $172,782 | $235,878 |
| Gross profit | — | −$206,172 | −$275,451 | −$234,258 | −$224,415 | −$165,249 | −$115,011 | $6,174 | $178,840 | $279,704 |
| Research & development | $1.8M | $3.2M | $5.0M | $6.6M | $5.5M | $5.9M | $6.6M | $4.7M | $1.9M | $495,377 |
| Sales, general & admin | $3.9M | $7.6M | $5.5M | $6.6M | $6.0M | $5.6M | $4.3M | $4.0M | $2.9M | $1.6M |
| Total operating expenses | $5.8M | $10.8M | $10.5M | $13.2M | $11.5M | $11.5M | $10.8M | $9.0M | $4.8M | $2.1M |
| Operating income | −$5.8M | −$10.8M | −$10.5M | −$13.2M | −$11.5M | −$11.5M | −$10.8M | −$9.0M | −$4.6M | −$1.8M |
| Interest expense | — | — | — | $21,533 | $267,055 | $232,426 | $2.4M | $729,241 | $0 | $0 |
| Income before taxes | −$7.0M | −$11.5M | −$10.1M | −$13.2M | −$11.2M | −$11.7M | −$13.3M | −$9.8M | −$5.4M | −$2.8M |
| Income taxes | — | — | −$1 | $21,533 | −$41,545 | $241,268 | $2.2M | −$777,253 | $750,904 | $983,611 |
| Net income | −$7.0M | −$11.5M | −$10.1M | −$13.2M | −$11.2M | −$11.7M | −$13.3M | −$9.8M | −$5.4M | −$2.8M |
| EBITDA | −$6.9M | −$11.3M | −$9.8M | −$12.9M | −$11.0M | −$11.3M | −$10.8M | −$9.0M | −$4.6M | −$1.7M |
| EPS (diluted) | −$8.63 | −$579.34 | −$3080.05 | −$6300.96 | −$7001.60 | −$22402.03 | −$39924.04 | −$2.26 | −$1.59 | −$14.20 |
| Gross margin | — | — | — | — | — | — | — | 100.0% | 50.9% | 54.3% |
| Operating margin | — | — | — | — | — | — | — | −146,080.5% | −1,315.6% | −347.5% |
| Net margin | — | — | — | — | — | — | — | −158,669.6% | −1,529.2% | −538.3% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $211,600 | $0 | $0 | $0 | $0 | $428,408 | $0 |
| Cost of revenue | — | $39,715 | $39,532 | $39,389 | $32,790 | $45,583 | — | — | $50,124 | $55,676 | $61,247 | $70,449 |
| Gross profit | — | −$39,715 | −$39,532 | −$39,389 | −$32,790 | −$45,583 | — | — | −$50,124 | −$55,676 | −$61,247 | −$70,449 |
| Research & development | $233,665 | $776,410 | $508,137 | $432,113 | $381,061 | $528,685 | $637,957 | $794,444 | $716,366 | $1.0M | $579,350 | $1.6M |
| Sales, general & admin | $1.2M | $1.4M | $1.1M | $938,590 | $920,029 | $940,597 | $3.7M | $714,570 | $1.5M | $1.7M | $878,430 | $1.5M |
| Total operating expenses | $1.5M | $2.1M | $1.6M | $1.4M | $1.3M | $1.5M | $4.3M | $1.5M | $2.2M | $2.8M | $1.5M | $3.1M |
| Operating income | −$1.5M | −$2.2M | −$1.6M | −$1.4M | −$1.3M | −$1.5M | −$4.3M | −$1.5M | −$2.2M | −$2.8M | −$1.5M | −$3.1M |
| Interest expense | — | — | — | — | — | — | — | $7.3M | — | — | $3,418 | — |
| Income before taxes | $159,944 | −$1.3M | −$3.2M | −$1.6M | −$1.2M | −$1.0M | −$4.1M | −$2.4M | −$2.2M | −$2.8M | −$1.5M | −$3.1M |
| Income taxes | — | — | — | — | — | −$1 | — | — | −$4 | $4 | $3 | $110,035 |
| Net income | $159,944 | −$1.3M | −$3.2M | −$1.6M | −$1.2M | −$1.0M | −$4.1M | −$2.4M | −$2.2M | −$2.8M | −$1.5M | −$3.1M |
| EBITDA | −$1.4M | −$1.3M | −$3.1M | −$1.6M | −$1.2M | −$990,747 | −$4.3M | $5.0M | −$2.2M | −$2.7M | −$1.4M | −$3.0M |
| EPS (diluted) | −$0.63 | −$1.09 | −$2.23 | −$2.10 | −$1.71 | −$2.59 | $25.20 | −$9.54 | −$140.00 | −$455.00 | −$0.05 | −$700.00 |
| Gross margin | — | — | — | — | — | −21.5% | — | — | — | — | −14.3% | — |
| Operating margin | — | — | — | — | — | −694.4% | — | — | — | — | −340.3% | — |
| Net margin | — | — | — | — | — | −489.8% | — | — | — | — | −340.7% | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in NDRA's financial statements (latest annual report filed March 31, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
NDRA financial results
ENDRA Life Sciences reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $7.0 million. Diluted earnings per share came to −$8.63.
See the NDRA stock overview for the latest quote and news, or the NDRA chart for price history and technical indicators.
NDRA income statement FAQ
Does ENDRA Life Sciences have revenue?
ENDRA Life Sciences reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is ENDRA Life Sciences profitable?
No. ENDRA Life Sciences reported a net loss of $7.0 million in fiscal 2025.
How much does ENDRA Life Sciences spend on research and development?
ENDRA Life Sciences spent $1.8 million on research and development in fiscal 2025.
What are ENDRA Life Sciences's earnings per share?
ENDRA Life Sciences earned $-8.63 per diluted share in fiscal 2025, compared with $-579.34 a year earlier.
When will ENDRA Life Sciences report its next earnings?
ENDRA Life Sciences is expected to report results for the quarter ending September 30, 2026 on November 13, 2026.
When does ENDRA Life Sciences's fiscal year end?
ENDRA Life Sciences's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 31, 2026.